ArticleRMD open2026
Head and neck cancer risk in patients with rheumatoid arthritis compared with matched controls: a nationwide cohort study.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAutoimmune rheumatic diseases, including rheumatoid arthritis (RA), have recently been associated with an increased risk of cancer, particularly head and neck cancer (HNC). This study aimed to assess the risk of HNCs in patients with RA, focusing on the impact of serological status and specific HNC sites.
methodsA retrospective cohort study was conducted using data from the Korean National Health Insurance Service. A total of 40 990 patients with RA were divided into seropositive and seronegative RA groups, matched with 204 950 non-RA controls. Cox proportional hazards models were used to calculate adjusted HRs (aHRs) for HNCs, adjusting for important covariates such as smoking, alcohol consumption and comorbidities.
resultsPatients with RA had an increased risk of overall HNCs (aHR: 1.53, 95% CI 1.12 to 2.09) compared with controls, with a significantly higher risk for pharyngeal cancer (aHR: 2.20, 95% CI 1.33 to 3.64). However, RA showed no significant association with oral, salivary or laryngeal cancer. The analysis stratified by seropositivity status revealed no significant difference in the risk of HNCs between seropositive and seronegative RA groups.
conclusionPatients with RA have an increased risk of developing overall HNCs, particularly pharyngeal cancer. However, no significant association was found for other HNC types. Further research is warranted to better understand the potential link between RA and increased pharyngeal cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.